ClinicalTrials.gg
Active, not recruitingNCT07944911Updated Nov 18, 2026

Changes in Taurine Levels After Non-Surgical Periodontal Treatment and Their Association With Inflammatory and Apoptosis Marker

An interventional study of Non-surgical periodontal treatment and Periodontally healthy group in Periodontal Disease, Saliva and Taurine, sponsored by Ordu University. Active, not recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Ordu University · Not applicable, Interventional, and Treatment

How we know

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 160 studies in Periodontal Diseases with a site in Turkey — 25 open to participants now, 34 under way, none of them phase 3. Periodontal Diseases · Turkey.

Enrollment
50th of 69
48 · median 60
Started
2026
with 21 others
No phase
66 of 160
11 open now
Primary completion
2027-03
later than 28 of 33 live
Registered
159th of 160
by date

Among the 160 studies in Periodontal Diseases with a site in Turkey, this one is the 50th largest by enrollment of the 69 interventional ones that give a count, is one of 22 that started in 2026, is one of 66 with no phase, reaches primary completion later than 28 of the 33 other live ones, and was the 159th registered.

Periodontal Diseases

871 studies on the registry are indexed under Periodontal Diseases; 191 are open to participants now.

Browse Periodontal Diseases studies →

Open to participants now

25 of the 160 studies in Periodontal Diseases with a site in Turkey are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 102 Periodontal Diseases studies recruiting now, 48 (47%) set no upper age limit and 42 (41%) stop at 75 or younger; 5 take children under 18; 59 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 160 studies in Periodontal Diseases with a site in Turkey, or all of them as a file.
02

Study summary

The aim of this study is to measure taurine, IL-1β, IL-10, myeloperoxidase, and caspase-3 levels in gingival crevicular fluid (GCF) and saliva of individuals with periodontal disease, to compare these parameters with those of periodontally healthy individuals, and to evaluate the associations between taurine levels and inflammatory and apoptotic markers. Furthermore, the study aims to compare changes in these parameters before and after non-surgical periodontal treatment in individuals with periodontal disease.

Read the detailed description

Taurine, a sulfur-containing amino acid, plays an important role in antioxidant and anti-inflammatory processes. Interleukin-1β (IL-1β), a pro-inflammatory cytokine, is a key mediator of periodontal inflammation and tissue destruction, whereas interleukin-10 (IL-10) is an anti-inflammatory cytokine that helps regulate inflammatory responses. Myeloperoxidase (MPO), a marker of neutrophil activation, contributes to the inflammatory response through the production of reactive oxidants, whereas caspase-3 is a key executioner enzyme involved in apoptosis and programmed cell death. This study aimed to investigate taurine, IL-1β, IL-10, MPO, and caspase-3 levels in saliva and gingival crevicular fluid (GCF) of individuals with periodontitis, gingivitis, and periodontal health, and to evaluate changes in these biomarkers following non-surgical periodontal treatment.

Materials and Methods: A total of 48 systemically healthy individuals were included in the study and divided into three groups: individuals with Stage III Grade B periodontitis, individuals with gingivitis, and periodontally healthy individuals. Clinical periodontal parameters, including the Silness and Löe Plaque Index (PI), Löe and Silness Gingival Index (GI), probing pocket depth (PPD), clinical attachment level (CAL), and bleeding on probing (BOP), were recorded. Routine radiographic examinations were also performed to assess alveolar bone levels.

Gingival crevicular fluid (GCF) and unstimulated saliva samples were collected from all three groups at baseline to determine taurine, IL-1β, IL-10, caspase-3, and MPO levels. In the gingivitis and periodontitis groups, clinical examinations and sample collection were repeated at the sixth week following non-surgical periodontal treatment. The levels of these biomarkers were quantified using enzyme-linked immunosorbent assay (ELISA).

03

Conditions studied

  • Periodontal Disease
  • Saliva
  • Taurine
  • Gingival Crevicular Fluid

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals diagnosed with Stage III Grade B periodontitis, gingivitis, or periodontal health.
  • Individuals aged 18 years or older.
  • Individuals who have signed the written form.

Exclusion criteria

Exclusion Criteria:

  • Individuals under 18 years of age.
  • Individuals with any systemic disease.
  • Pregnant or lactating women.
  • Women in the menopausal period.
  • Individuals who have received periodontal treatment prior to the study.
  • Individuals who do not provide written .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
48 participants (actual)

Study arms

  • Other
    Periodontally Healthy

    Systemically healthy and patients with periodontally healthy

    Other: Periodontally healthy group

  • Other
    Stage III Grade B Periodontitis

    systemically healthy and patients with Stage III Grade B periodontitis

    Other: Non-surgical periodontal treatment

  • Other
    Gingivitis

    Systemically healthy and patients with Gingivitis

    Other: Non-surgical periodontal treatment

Interventions

  • OtherNon-surgical periodontal treatment

    Non-surgical periodontal treatment consisting of supragingival scaling and subgingival instrumentation using periodontal scalers and curettes in individuals with Stage III Grade B periodontitis.

  • OtherPeriodontally healthy group

    Periodontally healthy individuals who did not receive periodontal treatment. GCF and unstimulated saliva samples were collected at baseline.

  • OtherNon-surgical periodontal treatment

    Professional supragingival scaling and plaque removal performed in individuals with gingivitis.

06

What researchers measure

Primary outcomes

  1. Plaque Index

    to assess plaque accumulation

    Time frame: Baseline

  2. Plaque Index

    to assess plaque accumulation

    Time frame: 6 weeks post-treatment

  3. Gingival Index

    for evaluating gingival inflammation

    Time frame: Baseline

  4. Gingival Index

    for evaluating gingival inflammation

    Time frame: 6 weeks post-treatment

  5. Probing pocket depth

    for measuring disease severity

    Time frame: Baseline

  6. Probing pocket depth

    for measuring disease severity

    Time frame: 6 weeks post-treatment

  7. clinical attachment level

    Clinical attachment level (CAL) is calculated by adding or subtracting probing depth (PD) and gingival recession (GR). The formula is CAL = PD + GR. CAL is measured in millimeters.

    Time frame: Baseline

  8. clinical attachment level

    Clinical attachment level (CAL) is calculated by adding or subtracting probing depth (PD) and gingival recession (GR). The formula is CAL = PD + GR. CAL is measured in millimeters.

    Time frame: 6 weeks post-treatment

  9. Bleeding on Probing

    to assess disease activity

    Time frame: Baseline

  10. Bleeding on Probing

    to assess disease activity

    Time frame: 6 weeks post-treatment

  11. IL-1β

    IL-1β levels in gingival crevicular fluid (GCF) and saliva

    Time frame: Baseline

  12. IL-1β

    IL-1β levels in gingival crevicular fluid (GCF) and saliva

    Time frame: 6 weeks post-treatment

  13. Taurine

    Taurine levels in gingival crevicular fluid (GCF) and saliva

    Time frame: Baseline

  14. Taurine

    Taurine levels in gingival crevicular fluid (GCF) and saliva

    Time frame: 6 weeks post-treatment

  15. Caspase-3

    Caspase-3 levels in gingival crevicular fluid (GCF) and saliva

    Time frame: Baseline

  16. Caspase-3

    Caspase-3 levels in gingival crevicular fluid (GCF) and saliva

    Time frame: 6 weeks post-treatment

  17. Myeloperoxidase

    Myeloperoxidase levels in gingival crevicular fluid (GCF) and saliva

    Time frame: Baseline

  18. Myeloperoxidase

    Myeloperoxidase levels in gingival crevicular fluid (GCF) and saliva

    Time frame: 6 weeks post-treatment

  19. IL-10

    IL-10 levels in gingival crevicular fluid (GCF) and saliva

    Time frame: Baseline

  20. IL-10

    IL-10 levels in gingival crevicular fluid (GCF) and saliva

    Time frame: 6 weeks post-treatment

07

Study locations

1 site
  • Figen ÖNGÖZ DEDE
    Altinordu, Ordu 52200, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2026 (actual). Primary completion is estimated for Mar 2027, 4 months after the start.

Of 314 non-industry interventional studies with no phase under Periodontal Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's planned 4 months is below that.

Counting every sponsor, half of 333 studies reached it within 13 months; a quarter within 8 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartActual
Nov 1, 2026
Primary completionEst.
Mar 2027
CompletionEst.
Aug 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07944911
Lead sponsor
Ordu University
Responsible party
Prof.Dr. Figen ÖNGÖZ DEDE (Clinical Professor, Ordu University) — Principal investigator
First posted
Nov 18, 2026
Start date
Nov 1, 2026
Primary completion
Mar 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Figen ÖNGÖZ DEDE, Professor
principal investigator · Ordu Universty

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion